The Genome Revolution¶
Richter, S. (2018). The Genome Revolution. "Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'".
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Shirky Principle
- In medicine and chronic-care infrastructure, clinics, device makers, and pharmaceutical franchises depend on ongoing management rather than cure.
This sourceDocuments the explicit financial logic that one-shot cures threaten recurring revenue versus chronic therapies — the medicine/chronic-care incentive favoring ongoing management over cure.
Supported in partVerified against the work's full text
The CNBC report of Goldman's note shows biotech cures weakening recurring revenue relative to chronic therapies, but says nothing about clinics or device makers.
“such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies”
- In medicine and chronic-care infrastructure, clinics, device makers, and pharmaceutical franchises depend on ongoing management rather than cure.
Verification¶
Does it exist? Not checked yet. This entry carries no identifier to resolve. It was extracted from the citation as written in the article, normalized, and deduplicated against the rest of the registry.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:e0d619be6b6a · see in the full table